The early phases of drug discovery use in silico models to rationalize structure activity relationships, and to predict the activity of novel compounds. However, the performance of these models is not always acceptable and the reliability of external predictions -both to novel compounds and to related protein targets -is often limited. Proteochemometric modeling [1] adds a target description, based on physicochemical properties of the binding site, to these models.
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Our proteochemometric models [2] are based on Scitegic circular fingerprints on the compound side and on a customized protein fingerprint on the target side. This protein fingerprint is based on a selection of physicochemical descriptors obtained from the AAindex database. Through PCA we selected a number of physicochemical properties which are hashed in a fingerprint using the Scitegic hashing algorithm. We compared this fingerprint to a number of protein descriptors previously published, including the Z-scales, the FAS-GAI and the BLOSUM descriptors. Our fingerprint performs superior to all of these. In addition, we show that proteochemometric models improve external prediction capabilities. In the case of classification this leads to models with a higher specificity when compared to conventional QSAR. In the case of regression our models show an average lower RMSE of 0.12 log units when based on a pIC50 output variable compared to conventional QSAR modeling the same data-set. Furthermore, our models enable target extrapolation. As a result we can predict the activity of known and new compounds on new targets while retaining the same model quality as when performing external validation without target extrapolation. 
